The normal coagulation time of the human body varies depending on the detection method.
The following are several common detection methods and their corresponding normal reference ranges:
1 Activated partial thromboplastin time (APTT):
The normal reference range is generally 25-37 seconds. APTT mainly reflects the function of coagulation factors VIII, IX, XI, XII, etc. in the intrinsic coagulation pathway.
2 Prothrombin time (PT):
The normal reference value is usually 11-13 seconds. PT is mainly used to evaluate the function of coagulation factors II, V, VII, X, etc. in the extrinsic coagulation pathway.
3 International normalized ratio (INR):
The normal reference range is between 0.8 and 1.2. INR is calculated based on the PT value and is used to monitor the therapeutic effect of oral anticoagulants (such as warfarin) to make the test results between different laboratories comparable.
4 Fibrinogen (FIB):
The normal reference range is 2-4g/L. FIB is a plasma glycoprotein synthesized by the liver and plays a key role in the coagulation process. It is converted into fibrin under the action of thrombin to form a blood clot.
It should be noted that the testing equipment and reagents of different laboratories may differ, and the specific normal reference values may be slightly different. In addition, some physiological factors (such as age, gender, pregnancy, etc.) and pathological factors (such as liver disease, blood system diseases, taking certain drugs, etc.) will also affect the coagulation time. Therefore, when interpreting the coagulation time results, a comprehensive analysis needs to be conducted in combination with the patient's specific situation.
BEIJING SUCCEEDER TECHNOLOGY INC.
CONCENTRATION SERVICE COAGULATION DIAGNOSIS
ANALYZER REAGENTS APPLICATION
Beijing Succeeder Technology Inc. (stock code: 688338) has been deeply engaged in the field of coagulation diagnosis since its establishment in 2003, and is committed to becoming a leader in this field. Headquartered in Beijing, the company has a strong R&D, production and sales team, focusing on the innovation and application of thrombosis and hemostasis diagnostic technology.
With its outstanding technical strength, Succeeder has won 45 authorized patents, including 14 invention patents, 16 utility model patents and 15 design patents. The company also has 32 Class II medical device product registration certificates, 3 Class I filing certificates, and EU CE certification for 14 products, and has passed ISO 13485 quality management system certification to ensure the excellence and stability of product quality.
Succeeder is not only a key enterprise of the Beijing Biomedicine Industry Leapfrog Development Project (G20), but also successfully landed on the Science and Technology Innovation Board in 2020, achieving leapfrog development of the company. At present, the company has built a nationwide sales network covering hundreds of agents and offices. Its products are sold well in most parts of the country. It is also actively expanding overseas markets and continuously improving its international competitiveness.